Safety and Efficacy of INGAP-Peptide in Patients With Type 1 Diabetes
Public ClinicalTrials.gov record NCT00071409. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Placebo-controlled, Rising Dose, Multicenter Study to Evaluate the Efficacy and Safety of 90 Days of 300 or 600 mg Daily Subcutaneous Injections of INGAP Peptide in Type I Diabetes Mellitus Patients
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Insulin is a chemical that the body needs in order to use or store sugar. It is made by a type of cell called a beta cell which resides in an organ known as the pancreas. Type 1 diabetes is a disease where the beta cells have been destroyed so that little or no insulin is made. Sugar levels rise in the blood as a result. INGAP-Peptide is being tested to attempt to create new beta cells in the pancreas, and to restore the ability to produce insulin in type 1 diabetic patients.
Study identification
- NCT ID
- NCT00071409
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 63 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 30, 2003
- Primary completion
- Apr 30, 2004
- Completion
- Apr 30, 2004
- Last update posted
- Jul 10, 2014
2003 – 2004
United States locations
- U.S. sites
- 10
- U.S. states
- 7
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Radiant Research | Irvine | California | 92618 | — |
| VA Hospital UCSD | San Diego | California | 92161 | — |
| Diablo Clinical Research | Walnut Creek | California | 94598 | — |
| MedStar Clinical Research Center | Washington D.C. | District of Columbia | 20003 | — |
| Springfield Diabetes and Endocrine Center | Springfield | Illinois | 62704 | — |
| Mercury Street Medical | Butte | Montana | 59701 | — |
| UNC Diabetes Care Center | Durham | North Carolina | 27713 | — |
| Clinical Research Institute of Southern Oregon | Medford | Oregon | 97504 | — |
| University of Texas Health Science Center - Texas Diabetes Institute | San Antonio | Texas | 78207 | — |
| DGD Research Associates | San Antonio | Texas | 78229 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00071409, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 10, 2014 · Synced Sep 10, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00071409 live on ClinicalTrials.gov.